Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 440-448

  Yonezawa, Takayuki ^a,b   Mase, Naomi ^b   Sasaki, Hiroaki ^c   Teruya, Toshiaki ^b,d   Hasegawa, Shin Ichi ^b   Cha, Byung Yoon ^b   Yagasaki, Kazumi ^a,e   Suenaga, Kiyotake ^c   Nagai, Kazuo ^b   Woo, Je Tae ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Apoptosis; Biselyngbyaside; Bone resorption; Differentiation; Macrolide; Osteoclast

Indexed keywords

BISELYNGBYASIDE; CASPASE 3; CASPASE INHIBITOR; MACROLIDE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYANOBACTERIUM; DRUG ISOLATION; LYNGBYA; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; COATED PITS, CELL-MEMBRANE; COCULTURE TECHNIQUES; HUMANS; MACROLIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NFATC TRANSCRIPTION FACTORS; OSCILLATORIA; OSTEOBLASTS; OSTEOCLASTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; VACUOLAR PROTON-TRANSLOCATING ATPASES;

CYANOBACTERIA; LYNGBYA;

EID: 84855551980     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23213     Document Type: Article

References (21)

1. Ajizian SJ, English BK, Meals EA. 1999. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis 179:939-944. (Pubitemid 29159340)
2. Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40:251-264. (Pubitemid 46054562)
3. Blunt JW, Copp BR, Munro MHG, Northcote PT, Prinsep MR. 2010. Marine natural products. Nat Prod Rep 27:165-237.
4. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342. (Pubitemid 40852708)
5. Driggers EM, Hale SP, Lee J, Terrett NK. 2008. The exploration of macrocycles for drug discovery-An underexploited structural class. Nat Rev Drug Discov 7:608-624. (Pubitemid 351927725)
6. Feng X. 2005. RANKing intracellular signaling in osteoclasts. IUBMB Life 57:389-395. (Pubitemid 41073120)
7. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP, Liew FY. 1999. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 163:6403-6412.
8. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. 2004. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279:13984-13992. (Pubitemid 38468932)
9. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-47372. (Pubitemid 36159251)
10. Miyazaki M, Fujikawa Y, Takita C, Tsumura H. 2007. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 26:231-239. (Pubitemid 46020250)
11. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. 2009. Drug development from marine natural products. Nat Rev Drug Discov 8:69-85.
12. Nishihara T, Akifusa S, Koseki T, Kato S, Muro M, Hanada N. 1995. Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death. Biochem Biophys Res Commun 212:255-262.
13. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. 1999. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274:19301-19308.
14. Okahashi N, Nakamura I, Jimi E, Koide M, Suda T, Nishihara T. 1997. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res 12:1116-1123. (Pubitemid 27264226)
15. Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289:1508-1514.
16. Teruya T, Sasaki H, Kitamura K, Nakayama T, Suenaga K. 2009. Biselyngbyaside, a macrolide glycoside from the marine cyanobacterium Lyngbya sp. Org Lett 11:2421-2424.
17. Woo JT, Ohba Y, Tagami K, Sumitani K, Yamaguchi K, Tsuji T. 1996. Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro. Biol Pharm Bull 19:297-299. (Pubitemid 26088605)
18. Woo JT, Nakagawa H, Notoya M, Yonezawa T, Udagawa N, Lee IS, Ohnishi M, Hagiwara H, Nagai K. 2004. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 27:504-509. (Pubitemid 41701834)
19. Xie QW, Kashiwabara Y, Nathan C. 1994. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705-4708. (Pubitemid 24239438)
20. Yonezawa T, Hasegawa S, Ahn JY, Cha BY, Teruya T, Hagiwara H, Nagai K, Woo JT. 2007. Tributyltin and triphenyltin inhibit osteoclast differentiation through a retinoic acid receptor-dependent signaling pathway. Biochem Biophys Res Commun 355:10-15. (Pubitemid 46273358)
21. Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT. 2011. Harmine, a beta-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Eur J Pharmacol 650:511-518.